Fig. 1 | npj Drug Discovery

Fig. 1

From: Development of potent, selective cPLA2 inhibitors for targeting neuroinflammation in Alzheimer’s disease and other neurodegenerative disorders

Fig. 1

a Best hits from the 1st Generation of cPLA2 screening. b Predicted binding poses of best hits in catalytic binding site of cPLA2 apo crystal structure (PDB ID 1CJY). The residues of cPLA2 active site are shown as gray sticks. The catalytic serine S228 and its catalytic partner D549 are shown in magenta. Hydrogen bonds are shown as blue dots.

Back to article page